Medtech enterprise TestCard has launched a ‘Test and Treat’ service using its at-home UTI test kit in partnership with European digital healthcare provider, Zava.
TestCard turns a smartphone camera into a clinical grade scanner, which along with its postcard test kit provides immediate results and a treatment referral where indicated.
Zava’s telemedicine platform provides access to consultations, testing and prescribed treatments from UK-based, GMC registered GPs. Since 2011, Zava’s doctors have carried out almost 5 million consultations.
The Test and Treat service, in partnership with Zava, allows users to order a test from Zava’s Online Doctor with a consultation and a prescription delivered directly to patients’ homes.
The TestCard app provides clear answers as to whether a UTI has been detected and, where necessary, directs patients back to Zava for clinical advice and support.
The test kit contains two tests and a free-to-download mobile application (available on iOS and Android), the TestCard solution is designed to be both affordable and accessible - to help reduce strain on the NHS and save time for both healthcare professionals and patients.
Dr Andrew Botham, co-founder & CSO at TestCard, said: “We are very excited to be launching a new partnership with Zava Online Doctor allowing alternative routes to important treatment for those that need it.
“Our aim is to make testing fast, accurate, and accessible for all. Our app provides clear results and next steps with no confusing medical jargon. A Zava online doctor, or other healthcare professional, can then use the detailed analysis to decide how best to treat you.”
Tom Barltrop, head of Zava UK, added: “By offering TestCard’s service on the Zava platform, our patients can be diagnosed, and where suitable provided with treatment, quickly and safely from the comfort of their own home.
“Zava’s mission is to provide our patients with healthcare that is dependable, affordable, and a fraction of today’s cost; our partnership with TestCard is an exciting step which will benefit the millions of patients who use the Zava platform in the UK and Europe.”
